ICBs are a class of antitumour immunotherapeutic drugs that suppress immune checkpoint molecules, such as PD-1, PD-L1, CTLA-4 and TIGIT, to restore immune recognition and immunogenicity in HCC [37–39]. This evidence concerns the gene TIGIT and hepatocellular carcinoma.